Company profile

Ticker
QTRX
Exchange
CEO
E. Kevin Hrusovsky
Employees
Incorporated in
Location
Fiscal year end
SEC CIK

QTRX stock data

(
)

Calendar

6 Aug 19
17 Sep 19
31 Dec 19

News

Company financial data Financial data

Quarter (USD) Jun 19 Mar 19 Dec 18 Sep 18
Revenue 13.54M 12.34M 10.88M 10.59M
Net income -10.56M -9.41M -9.33M -7.66M
Net profit margin -78.04% -76.23% -85.81% -72.30%
Operating income -10.51M -9.36M -9.41M -7.66M
Net change in cash 38.05M 32.15M -49.6M -9.05M
Cash on hand 72.03M 33.97M 1.82M 51.42M
Cost of revenue 6.61M 6.33M 5.67M 5M
Annual (USD) Dec 18 Dec 17 Dec 16
Revenue 37.63M 22.87M 17.59M
Net income -31.54M -27.02M -23.17M
Net profit margin -83.80% -118% -132%
Operating income -31.55M -26.01M -21.71M
Net change in cash 321K -28.17M
Cash on hand 1.82M 1.5M 29.67M
Cost of revenue 19.68M 12.89M 9.84M

Financial data from Quanterix earnings reports

Financial report summary

?
Risks
  • The anticipated benefits of the acquisition of Uman may not be realized.
  • Our future results may be adversely impacted if we do not effectively manage our expanded operations.
Management Discussion
  • Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC. In addition to historical information, the following discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results, performance or experience could differ materially from what is indicated by any forward-looking statement due to various important factors, risks and uncertainties, including, but not limited to, those set forth under “Special Note Regarding Forward-Looking Statements” included elsewhere in this quarterly report or under “Risk Factors” in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2018 or other filings that we make with the SEC.
  • We are a life sciences company that has developed next generation, ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Our platforms are based on our proprietary digital “Simoa” detection technology. Our Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers in extremely low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies, and also allow researchers to define and validate the function of novel protein biomarkers that are only present in very low concentrations and have been discovered using technologies such as mass spectrometry. These capabilities provide our customers with insight into the role of protein biomarkers in human health that has not been possible with other existing technologies and enable researchers to unlock unique insights into the continuum between health and disease. We believe this greater insight will enable the development of novel therapies and diagnostics and facilitate a paradigm shift in healthcare from an emphasis on treatment to a focus on earlier detection, monitoring, prognosis and, ultimately, prevention. We are currently focusing on protein detection, which we believe is an area of significant unmet need and where we have significant competitive advantages. However, in addition to enabling new applications and insights in protein analysis, we are also developing our Simoa bead-based technology to detect nucleic acids in biological samples.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: AB, addressed, alternative, attention, comprised, divert, ELISA, encountered, firm, forma, inability, incomplete, integrate, integration, longer, manner, neurodegenerative, neurofiliment, par, past, premier, pro, realize, realized, RSU, scale, size, solution, source, successfully, Sweden, Swedish, Uman, Umea, unable, unforeseen
Removed: adjusted, attributable, authorized, comparative, continued, Delaware, delaying, effected, incorporation, largely, ratio, reclassified, restated, retroactively, reverse, Secretary, split, state, unchanged